NEW YORK (GenomeWeb) – Cancer genetics diagnostics firm NeoGenomics today said that revenues in the second quarter increased 33 percent year over year while test volume increased 40 percent.

During the three months ended June 30, the Ft. Myers, Fla.-based company recorded $20.7 million in revenues, up from $15.6 million in the year-ago quarter. It beat the consensus analyst estimate of $19.8 million.

The number of tests performed in the quarter was up to 45,475 from 32,519 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.